Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 21, 2026 04:49 ET | Source: Research and Markets

Bispecific Antibody Drug Conjugates Market Landscape Report 2026: A $2 Billion Opportunity by 2030 with the 1st Approved BsADC by 2028 - Clinical Trials, Regulatory Approvals, Development Platforms

Dublin, April 21, 2026 (GLOBE NEWSWIRE) -- The "Bispecific Antibody Drug Conjugates Clinical Trials, Regulatory Approvals, Development Platforms & Market Opportunity Insight 2026" report has...
April 21, 2026 04:34 ET | Source: Research and Markets

Bispecific Antibody Market Landscape Report 2026: A Potential $60 Opportunity by 2031 - Insight on More than 550 Clinical Trials - Antibody Dosage, Patent, Price, Sales & Outlook

Dublin, April 21, 2026 (GLOBE NEWSWIRE) -- The "Bispecific Antibody Market Opportunity, Antibody Dosage, Patent, Price, Sales & Clinical Trials Outlook 2031" report has been added to ...
April 14, 2026 21:00 ET | Source: Shanghai EpimAb Biotherapeutics Co., Ltd.

EpimAb Biotherapeutics to Present a Novel Prodrug T-Cell Engager (ProTCE) Platform at the 2026 American Association for Cancer Research Annual Meeting

SHANGHAI, April 15, 2026 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T-cell engagers, is pleased...
April 14, 2026 03:30 ET | Source: Mestag Therapeutics

Mestag Therapeutics Selected to Present Targeted LTBR Agonist MST‑0312 in Late‑Breaking Session at AACR Annual Meeting

Mestag Therapeutics Selected to Present Targeted LTBR Agonist MST‑0312 in Late‑Breaking Session at AACR Annual Meeting
April 13, 2026 05:47 ET | Source: Research and Markets

Bispecific Antibodies Market Research and Competitive Landscape Report 2026: Comprehensive Insights Into Over 180 Companies and 250 Drugs

Dublin, April 13, 2026 (GLOBE NEWSWIRE) -- The "Bispecific Antibodies - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering. The report offers comprehensive...
February 20, 2026 10:56 ET | Source: Research and Markets

Glypican-3 (GPC3) Targeted Therapy Market Competitor Analysis Report 2026: More Than 20 Product Candidates are in Clinical Development and Further Eight at IND or IND-enabling Stage

Dublin, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The "Glypican-3 (GPC3) Targeted Therapy: a Competitor Analysis" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence...
February 09, 2026 20:00 ET | Source: Shanghai EpimAb Biotherapeutics Co., Ltd.

EpimAb Biotherapeutics Announces the First CTA Filing of a FIT-IG® Bispecific Antibody by its License Partner Almirall

SHANGHAI, Feb. 10, 2026 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, a clinical stage biopharmaceutical company specializing in the development of novel multispecific antibodies, today announced the...
January 21, 2026 04:52 ET | Source: Research and Markets

U.S. Bispecific Antibodies Forecast Report 2025-2033: Market to Grow by Over $260 Billion, Driven by Increased Cancer and Autoimmune Diseases, FDA Approvals, and Strategic Partnerships

Dublin, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The "U.S. Bispecific Antibodies Market Forecast to 2033" report has been added to ResearchAndMarkets.com's offering.The U.S. bispecific antibodies market...
December 10, 2025 09:15 ET | Source: Research and Markets

China Leads Therapeutic Access with 74 Approved Immuno-Oncology Agents

Dublin, Dec. 10, 2025 (GLOBE NEWSWIRE) -- The "Strategic Intelligence: Immuno-oncology (2025)" has been added to ResearchAndMarkets.com's offering. The latest report delves into the dynamic...
December 02, 2025 06:41 ET | Source: Research and Markets

Human Leukocyte Antigen (HLA) Targeted Therapy Market Research 2026: Advances Driven by Novel CAR-Treg and Bispecific T-Cell Engager Programs from Quell Therapeutics and Daiichi Sankyo

Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The "Human Leukocyte Antigen (HLA) Targeted Therapy, Clinical Trials, Therapeutic Approaches & Market Opportunity Insight 2026" report has been added to...